24 posts • ChatGPT (GPT-4o)
Updated
Ascletis has entered the obesity drug market with two ongoing U.S. Phase I clinical trials for its small molecule GLP-1R agonist ASC30. This new drug is being tested for both once-monthly subcutaneous injection and once-daily oral tablet forms. The chemical structure of ASC30 is indicated to be a derivative of Pfizer Gliprons. The rise in popularity of GLP-1 drugs like Ozempic and Mounjaro as weight loss aids has led to increased misuse and complications, prompting emergency departments across the GCC to report a surge in related cases. Additionally, the demand for these medications has caused shortages, affecting both weight loss seekers and diabetes patients. Meanwhile, experts caution against the severe side effects of using such drugs for weight loss purposes. An expert predicts that around 40% of the U.S. population is currently obese and this number could reach 50% in 10 years.
